The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of chronically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer (BRCA-wt).
Shannon Leigh Huggins-Puhalla
No relevant relationships to disclose
Jan Hendrik Beumer
No relevant relationships to disclose
Leonard Joseph Appleman
No relevant relationships to disclose
Hussein Abdul-Hassan Tawbi
No relevant relationships to disclose
Ronald G. Stoller
No relevant relationships to disclose
Yan Lin
No relevant relationships to disclose
Brian Kiesel
No relevant relationships to disclose
Antoinette R. Tan
No relevant relationships to disclose
Darlene Gibbon
No relevant relationships to disclose
Yixing Jiang
No relevant relationships to disclose
Agustin Garcia
No relevant relationships to disclose
Helen K. Chew
No relevant relationships to disclose
Robert Morgan
No relevant relationships to disclose
Stacie Peacock Shepherd
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
Vincent L. Giranda
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
Alice P. Chen
No relevant relationships to disclose
Chandra Prakash Belani
No relevant relationships to disclose
Edward Chu
No relevant relationships to disclose